CML clinical trials at UCSD
1 in progress, 0 open to new patients
Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.
Sorry, in progress, not accepting new patients
To evaluate molecular relapse free rates 6 months after stopping nilotinib therapy in patients who achieve MR4.5
La Jolla, California and other locations